The first-ever randomized trial of REBOA - a device once hailed as a revolution in trauma resuscitation - was stopped early because it appeared to increase mortality, not reduce it. The UK-REBOA trial, first published in JAMA in October 2023 and reinforced by the 2025 EAST Practice Management Guideline that now conditionally recommends against REBOA in hemodynamically unstable trauma patients, PubMed has ignited one of the fiercest debates in modern trauma surgery. The controversy strikes at a fundamental question every ATLS candidate should grapple with: how do we adopt new technologies in trauma, and what happens when the first rigorous evidence contradicts years of observational enthusiasm? For trainees studying for the ATLS exam, this story offers a masterclass in evidence-based surgery, Bayesian trial design, and the gap between physiologic rationale and clinical reality.
From military innovation to civilian operating rooms
REBOA - Resuscitative Endovascular Balloon Occlusion of the Aorta - involves threading a catheter into the aorta and inflating a balloon to temporarily occlude blood flow, The Bottom Line acting as a less invasive bridge to definitive hemorrhage control in patients with non-compressible torso hemorrhage. The concept is not new; aortic occlusion balloons were used in the Korean War. But modern iterations, particularly the ER-REBOA catheter developed by Prytime Medical, made the procedure faster and feasible in emergency departments rather than operating theaters.
Adoption accelerated rapidly through the 2010s. Observational data from military and civilian centers was encouraging. First10EM A physiological rationale was compelling: occluding the aorta proximal to the injury should increase afterload, redirect blood to the heart and brain, and buy time for definitive repair. The Bottom Line By 2020, REBOA was being performed at major trauma centers worldwide, with advocates including Jonathan Morrison (R Adams Cowley Shock Trauma Center) and Megan Brenner (UCLA) publishing prolifically on its potential. Training courses multiplied. The technology felt like a logical extension of damage control resuscitation - elegant, minimally invasive, and life-saving in theory.
The problem was that no randomized controlled trial had ever tested whether it actually worked. Every positive study was observational, susceptible to selection bias and confounding. First10EM The trauma community was, in effect, performing a massive uncontrolled experiment on dying patients.
The UK-REBOA trial: first RCT, devastating results
The UK-REBOA trial, led by Jan O. Jansen (University of Aberdeen) and published in JAMA in November 2023, was designed as a pragmatic, Bayesian, multicenter RCT across 16 major trauma centres in England and Scotland. Springer Between October 2017 and March 2022, 90 patients with suspected exsanguinating torso hemorrhage were randomized: 46 to REBOA plus standard care and 44 to standard care alone. PubMed
The results were stark. Ninety-day mortality was 54% in the REBOA group versus 42% in the standard care group. The trial triggered its pre-specified Bayesian stopping rule for harm The Bottom Line — the posterior probability that REBOA increased mortality exceeded 86.9% (adjusted OR 1.58, 95% CrI 0.72–3.52). Mortality was higher in the REBOA arm at every measured time point: 3 hours, 6 hours, 24 hours, in-hospital, and 6 months. The Bottom Line
Several operational findings compounded the concern. Only 19 of 46 patients (41%) randomized to REBOA actually had the balloon successfully inflated. The median time from ED arrival to inflation was 32 minutes (IQR 20–47). The Bottom Line The arterial access failure rate was 17%. First10EM These numbers suggest that in the UK trauma system - with median prehospital times exceeding 90 minutes First10EM - the procedure introduced delays and complications without delivering its theoretical hemodynamic benefits in time to matter.
The counterattack: why REBOA proponents say the trial is flawed
The response from REBOA advocates was swift, detailed, and fierce. In 2024, Martínez Hernández et al. published a formal reanalysis in the American Journal of Surgery The American Journal of Surgery titled "Has the balloon really burst?" (PubMed: https://pubmed.ncbi.nlm.nih.gov/38670836/). Using Bayesian logistic regression, they found no statistically significant difference between groups (p=0.3341) and argued the trial's conclusions "cannot be considered benchmarks." PubMedThe American Journal of Surgery
The criticisms fall into several categories:
Sample size and statistical power. With only 90 patients (and just 19 successful REBOA deployments), the trial was drastically underpowered. Springer Critics argue that stopping a trial this small for "harm" on a Bayesian threshold risks a false signal - the confidence intervals are wide enough to include both substantial benefit and substantial harm.
Baseline imbalances. The REBOA group had a lower median prehospital systolic blood pressure (84 mmHg vs. 99 mmHg) The Bottom Line and more traumatic brain injuries. These imbalances, in a trial of 90 patients, could easily account for the mortality difference. EAST The adjusted analysis attempted to correct for this but remained imprecise. The Bottom Line
System-level problems, not device problems. The UK major trauma network involves long prehospital times (often exceeding 90 minutes), meaning patients arrived profoundly shocked. Springer The 32-minute median time to balloon inflation after ED arrival suggests institutional inexperience — high-volume US centers report deployment in under 10 minutes. Only 19 successful deployments across 16 centres over nearly 5 years means roughly one deployment per centre every four years. EAST Critics argue this is a trial of REBOA in a system unready to deliver it, not a trial of REBOA itself. Springer
Predominantly blunt trauma. The UK trauma population is overwhelmingly blunt mechanism. Springer REBOA may have different efficacy profiles in penetrating trauma, where hemorrhage sources are more likely to be surgically accessible.
These arguments were summarized by a CJEM commentary (https://link.springer.com/article/10.1007/s43678-024-00680-w) and detailed critical appraisals on First10EM (https://first10em.com/the-uk-reboa-trial/) and The Bottom Line (https://www.thebottomline.org.uk/summaries/icm/emergency-department-resuscitative-endovascular-balloon-occlusion-of-the-aorta-in-trauma-patients-with-exsanguinating-hemorrhage/).
EAST 2025 guideline draws a line in the sand
In 2025, the Eastern Association for the Surgery of Trauma published its definitive Practice Management Guideline on REBOA, incorporating 31 studies in a systematic review and meta-analysis PubMed (PubMed: https://pubmed.ncbi.nlm.nih.gov/40166770/). Led by Melike Harfouche and George Kasotakis, the guideline made two crucial recommendations:
- Conditionally recommends AGAINST REBOA in hemodynamically unstable trauma patients with suspected subdiaphragmatic hemorrhage PubMed - the primary scenario for which the device was designed and marketed.
Conditionally recommends FOR REBOA in traumatic cardiac arrest and for prophylactic placement in placenta accreta spectrum PubMed - narrower, specific indications where alternative evidence exists.
This represents a remarkable reversal for a technology that had been rapidly proliferating. The conditional (rather than strong) nature of the recommendation reflects the acknowledged weakness of the evidence base - essentially one small RCT and observational data - but the direction of the recommendation is unmistakable. EAST is telling trauma surgeons: based on current evidence, do not use REBOA as your go-to for the bleeding patient in shock.
The guideline creates a practical challenge for centres that invested heavily in REBOA training and equipment. It also raises medicolegal questions: if a patient dies during or after REBOA deployment, and a professional society has recommended against its use in that exact scenario, what is the standard of care?
Why this matters beyond REBOA: the broader resuscitation revolution
The REBOA controversy is best understood within the larger paradigm shift transforming trauma resuscitation in 2024–2025 - a shift now codified in the ATLS 11th Edition launched in July 2025.
The most headline-grabbing change in ATLS 11 is the move from ABCDE to xABCDE, where "x" stands for eXsanguinating hemorrhage control. American College of Surgeons For decades, ATLS dogma held that airway always comes first. The new framework acknowledges that a patient exsanguinating from an extremity wound needs hemorrhage control before anything else - a philosophy supported by the Ferrada et al. multicenter trial (World J Emerg Surg 2024; PubMed: https://pubmed.ncbi.nlm.nih.gov/38664763/), which found a 91% reduction in odds of 24-hour mortality with a circulation-first (CAB) versus airway-first (ABC) approach in massively hemorrhaging patients (24-hour mortality: 11.1% CAB vs. 69.2% ABC). PubMed
Other critical elements of the 2024–2025 resuscitation revolution include:
- The 2024 AAST/ACS-COT Damage Control Resuscitation Protocol (J Trauma Acute Care Surg 2024; https://journals.lww.com/jtrauma/fulltext/2024/03000/american_association_for_the_surgery_of.23.aspx) - the first joint national clinical protocol emphasizing crystalloid minimization, 1:1:1 balanced transfusion, permissive hypotension (target SBP 80–90 mmHg), TXA within 3 hours, and whole blood where available. Lippincott Williams & Wilkins
- EAST's 2024 conditional recommendation for whole blood in civilian trauma (https://www.east.org/education-resources/practice-management-guidelines/details/whole-blood-resuscitation-for-injured-patients-requiring-transfusion-a-systematic-review-metaanalysi), with the definitive TROOP trial (NCT05638581) now enrolling across 15 US Level I trauma centers. PubMed CentralSpringer
- The TRAIN trial (JAMA 2024; https://pubmed.ncbi.nlm.nih.gov/39382241/) showing that liberal transfusion (Hb threshold <9 g/dL) significantly improves neurological outcomes after acute brain injury versus restrictive thresholds (Hb <7 g/dL), PubMed with a number needed to treat of 10 Thesgem — overturning 25 years of restrictive transfusion dogma.
- The ongoing TXA debate, crystallized by the 2025 NAEMSP/ACS-COT/ACEP Joint Position Statement Lippincott Williams & Wilkins (https://journals.lww.com/jtrauma/fulltext/2025/09000/tranexamic_acid_in_trauma__a_joint_position.6.aspx) which acknowledged that evidence for TXA in civilian trauma remains "both limited and contradictory" Lippincott Williams & Wilkins - a striking admission given the drug's widespread adoption following CRASH-2.
REBOA was supposed to be part of this revolution. Instead, it has become a cautionary tale about the gap between physiologic plausibility and clinical effectiveness - a reminder that trauma surgery's history is littered with interventions that made perfect sense on a whiteboard but failed in randomized trials.
What ATLS candidates need to know
For trainees preparing for the ATLS exam, the REBOA controversy offers several testable and conceptual lessons:
On REBOA specifically: Understand the device, its zones of deployment (Zone I for abdominal/pelvic hemorrhage, Zone III for pelvic/junctional hemorrhage), The Bottom Line and its theoretical mechanism. But also know that the only RCT was stopped early for potential harm, Springer and that EAST now recommends against its use in hemodynamically unstable trauma patients with suspected subdiaphragmatic hemorrhage. REBOA may still have a role in traumatic cardiac arrest and specific obstetric scenarios. PubMed
On the broader paradigm shift: The ATLS 11th Edition's adoption of xABCDE means candidates must understand when catastrophic hemorrhage control takes priority over airway management. American College of Surgeons The integration of Shock Index (HR/SBP) as a key assessment metric, the emphasis on damage control resuscitation principles, and the reduced role of crystalloid in favor of early blood products are all examinable changes.
On evidence-based surgery: The REBOA story illustrates why observational data cannot substitute for randomized trials. It also illustrates the limitations of small trials stopped early, the impact of system-level factors on device performance, and the tension between innovation and evidence in acute surgical care.
The key papers every trauma trainee should read on this topic:
- UK-REBOA Trial - Jansen et al., JAMA 2023 (https://pubmed.ncbi.nlm.nih.gov/37824132/)
- EAST REBOA PMG 2025 (https://pubmed.ncbi.nlm.nih.gov/40166770/)
- Martínez Hernández reanalysis - American Journal of Surgery 2024 (https://pubmed.ncbi.nlm.nih.gov/38670836/)
- AAST/ACS-COT DCR Protocol 2024 (https://journals.lww.com/jtrauma/fulltext/2024/03000/american_association_for_the_surgery_of.23.aspx)
- ATLS 11th Edition overview — Injury 2025 (https://www.sciencedirect.com/science/article/abs/pii/S0020138326000665)
Conclusion: the question REBOA really asks
The REBOA debate is not just about a balloon catheter. It is about how trauma surgery evaluates and adopts innovation - and whether the field has the intellectual honesty to reverse course when evidence demands it. EAST's 2025 guideline represents exactly that kind of course correction, but the story is far from over. REBOA proponents rightly note that a single 90-patient trial in one trauma system cannot definitively condemn a technology. McGovern Medical School Future trials in higher-volume centres with faster deployment times may yet vindicate the device. The American Journal of Surgery
For now, the practical message is clear: REBOA is not dead, but its indications have narrowed dramatically. The days of enthusiastic deployment for any patient in hemorrhagic shock are over. What replaces it - faster surgery, whole blood, xABCDE protocols, prehospital blood products - represents a trauma resuscitation paradigm that is less about a single technological fix and more about getting the fundamentals right, faster. That, ultimately, is what ATLS has always been about.